» Authors » Jerome Place

Jerome Place

Explore the profile of Jerome Place including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 952
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Renard E, Joubert M, Villard O, Dreves B, Reznik Y, Farret A, et al.
Diabetes Care . 2023 Sep; 46(12):2180-2187. PMID: 37729080
Objective: Assess the safety and efficacy of automated insulin delivery (AID) in adults with type 1 diabetes (T1D) at high risk for hypoglycemia. Research Design And Methods: Participants were 72...
2.
Coutant R, Bismuth E, Bonnemaison E, Dalla-Vale F, Morinais P, Perrard M, et al.
Diabetes Technol Ther . 2023 Mar; 25(6):395-403. PMID: 36927054
It is unclear whether hybrid closed-loop (HCL) therapy attenuates the metabolic impact of missed or suboptimal meal insulin bolus compared with sensor-augmented pump (SAP) therapy in children with type 1...
3.
Renard E, Tubiana-Rufi N, Bonnemaison E, Coutant R, Dalla-Vale F, Bismuth E, et al.
Diabetes Obes Metab . 2021 Nov; 24(3):511-521. PMID: 34816597
Aim: To assess the safety and efficacy of hybrid closed-loop (HCL) insulin delivery 24/7 versus only evening and night (E/N), and on extended 24/7 use, in free-living children with type...
4.
He J, Renard E, Lord P, Cohen D, Cem-Duranty E, Place J, et al.
J Control Release . 2021 Jun; 336:1-15. PMID: 34118339
Continuous intraperitoneal insulin infusion, from an implanted insulin pump connected to a catheter that delivers insulin directly to the peritoneal cavity has many clinical advantages for patients with Type 1...
5.
Renard E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, Dalla-Vale F, Farret A, et al.
Diabetes Obes Metab . 2018 Jul; 21(1):183-187. PMID: 30047223
This randomized control trial investigated glucose control with closed-loop (CL) versus threshold-low-glucose-suspend (TLGS) insulin pump delivery in pre-pubertal children with type 1 diabetes in supervised hotel conditions. The patients [n ...
6.
Dassau E, Renard E, Place J, Farret A, Pelletier M, Lee J, et al.
Diabetes Obes Metab . 2017 May; 19(12):1698-1705. PMID: 28474383
Aims: To compare intraperitoneal (IP) to subcutaneous (SC) insulin delivery in an artificial pancreas (AP). Research Design And Methods: Ten adults with type 1 diabetes participated in a non-randomized, non-blinded...
7.
Marchand L, Luigi P, Place J, Dalla-Vale F, Farret A, Renard E
Diabetes Care . 2017 Apr; 40(6):e69-e70. PMID: 28385685
No abstract available.
8.
Renard E, Place J, Benbrahim N, Diouri O, Farret A
Rev Infirm . 2017 Apr; 66(230):35-37. PMID: 28366258
Almost 45 000 patients with type 1 diabetes are concerned in France by outpatient insulin pump therapy. The first systems of insulin pump therapy guided by glycaemia have evolved driven...
9.
Marchand L, Kawasaki-Ogita Y, Place J, Fayolle C, Lauton D, Boulet F, et al.
J Diabetes Sci Technol . 2017 Mar; 11(5):924-929. PMID: 28303725
Background: We investigated the long-term effects of continuous subcutaneous insulin infusion (CSII) on glucose control and microvascular complications in patients with type 1 diabetes (T1D). Methods: A total of 157...
10.
Renard E, Farret A, Kropff J, Bruttomesso D, Messori M, Place J, et al.
Diabetes Care . 2016 May; 39(7):1151-60. PMID: 27208331
Objective: After testing of a wearable artificial pancreas (AP) during evening and night (E/N-AP) under free-living conditions in patients with type 1 diabetes (T1D), we investigated AP during day and...